Tuberculosis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
Conditions: Pulmonary TB; Pulmonary Tuberculosis; Drug Sensitive Tuberculosis Interventions: Drug: TBAJ-876; Drug: Pretomanid; Drug: Linezolid; Drug: Bedaquiline; Drug: HRZE; Drug: HR Sponsors: Global Alliance for TB Drug Development Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials

Pragmatic Optimized Rifampicin Trial
Condition: Tuberculosis, Pulmonary Interventions: Drug: Optimised dose rifampicin; Drug: Standard dose rifampicin Sponsor: Radboud University Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Pragmatic Optimized Rifampicin Trial
Conditions: Tuberculosis, Pulmonary Interventions: Drug: Optimised dose rifampicin; Drug: Standard dose rifampicin Sponsors: Radboud University Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis
Conditions: Isoniazid; Tuberculosis; Acetylation Intervention: Sponsor: Centre Hospitalier Universitaire, Amiens Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Relevance of Isoniazid Dosage in Adults Treated for Tuberculosis
Conditions: Isoniazid; Tuberculosis; Acetylation Sponsors: Centre Hospitalier Universitaire, Amiens Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF ®10b
Condition: Healthy Interventions: Biological: H107e; Biological: CAF®10b; Biological: H107e/CAF®10b - low adjuvant dose; Biological: H107e/CAF®10b - full adjuvant dose; Biological: Low dose intranasal H107e; Biological: Full dose intranasal H107e; Biological: H107e/CAF®10b; Biologica l: i.m. placebo; Biological: BCG; Biological: i.d. placebo; Biological: Intranasal H107e Sponsors: Statens Serum Institut; Aurum Institute; Bill and Melinda Gates Foundation; Leiden University Medical Center; South African Tuberculosis Vaccine Init...
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107/CAF ®10b
Condition: Healthy Interventions: Biological: H107e; Biological: CAF®10b; Biological: H107e/CAF®10b - low adjuvant dose; Biological: H107e/CAF®10b - full adjuvant dose; Biological: Low dose intranasal H107e; Biological: Full dose intranasal H107e; Biological: H107e/CAF®10b; Biologica l: i.m. placebo; Biological: BCG; Biological: i.d. placebo; Biological: Intranasal H107e Sponsors: Statens Serum Institut; Aurum Institute; Bill and Melinda Gates Foundation; Leiden University Medical Center; South African Tuberculosis Vaccine Init...
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials